Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3 Neoplasms 2 Triple Negative Breast Neoplasms 1 Skin Diseases 1 Prostatic Neoplasms 1 Neoplasms by Site 1 Breast Diseases 1

Interventions

Prednisone 53 Radiotherapy 52 Docetaxel 51 Leuprolide 48 Goserelin 47 bicalutamide 45 enzalutamide 28 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27 Androgen Antagonists 27 Flutamide 24 Triptorelin Pamoate 22 apalutamide 18 Gonadotropin-Releasing Hormone 18 Abiraterone Acetate 17 Radiation 15 abiraterone 14 Zoledronic Acid 14 Magnetic Resonance Spectroscopy 13 gallium 68 PSMA-11 12 Prednisolone 11 luprolide acetate gel depot 10 darolutamide 9 Radiosurgery 9 cabazitaxel 8 Standard of Care 8 Specimen Handling 8 Radiotherapy, Intensity-Modulated 8 Radiotherapy, Conformal 8 Estramustine 8 Dexamethasone 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × ipatasertib × Clear all

NCT03072238 2025-06-06

IPATential150

Hoffmann-La Roche

Phase 3 Completed

1,101 enrolled 35 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡